PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18616678-5	2008	Preclinical investigations have shown antitumor activity and effectiveness of the BRAF kinase inhibitor Sorafenib and the proteasome inhibitor Bortezomib.	Sorafenib	104-113	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	82-86